Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/21/2025 | $21.00 | Peer Perform → Outperform | Wolfe Research |
| 3/5/2025 | $30.00 | Buy | H.C. Wainwright |
| 2/28/2025 | $45.00 → $13.00 | Overweight → Neutral | Analyst |
| 2/28/2025 | $9.00 | Neutral → Sell | Goldman |
| 1/27/2025 | $56.00 → $11.00 | Overweight → Equal-Weight | Morgan Stanley |
| 2/23/2024 | $136.00 → $32.00 | Buy → Neutral | Goldman |
| 2/15/2024 | Peer Perform | Wolfe Research | |
| 4/13/2023 | $66.00 | Buy | Canaccord Genuity |
Wolfe Research upgraded Intellia Therapeutics from Peer Perform to Outperform and set a new price target of $21.00
H.C. Wainwright initiated coverage of Intellia Therapeutics with a rating of Buy and set a new price target of $30.00
Analyst downgraded Intellia Therapeutics from Overweight to Neutral and set a new price target of $13.00 from $45.00 previously
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)
4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)